Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and/or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Patients With Stable Ischemic Heart Disease and Preserved Left Ventricular Systolic Function

Slide: 13 of 29

Comparative Effectiveness Review: Outcomes of Interest

A comparative effectiveness review (CER) titled, Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin II-Receptor Blockers (ARBs) Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease (IHD), was developed by the University of Connecticut/Hartford Hospital Evidence-based Practice Center for the Agency for Healthcare Research and Quality (AHRQ) and published online (available at: http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=334). This CER was based on a comprehensive systematic review of the literature. The methods for developing this CER followed the Methods Reference Guide for Effectiveness and Comparative Effectiveness Reviews, Version 1.0, published by AHRQ (available at http://effectivehealthcare.ahrq.gov/repFiles/2007_10DraftMethodsGuide.pdf).

The clinical outcomes and harms of interest are outlined in this slide and were determined a priori.